Skip to content

Prospective Study on Integrating Preoperative Radiomics and Clinical Features for Predicting Postoperative Renal Function after Partial Nephrectomy

Prospective Study on Integrating Preoperative Radiomics and Clinical Features for Predicting Postoperative Renal Function after Partial Nephrectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110253
Enrollment
Unknown
Registered
2025-10-11
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decline in kidney function / renal insufficiency Reduced urine output Edema (leg or generalized swelling) Worsening hypertension Fatigue and weakness Electrolyte imbalance (e.g., hyperkalemia)

Interventions

Kidney tumor patient group:None

Sponsors

Zhejiang Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with pathologically confirmed or radiologically highly suspected renal cell carcinoma (RCC), meeting the clinical diagnostic criteria for locally advanced or high-risk RCC, and planned for surgical resection; 2.Scheduled to undergo radical or partial nephrectomy, with postoperative adjuvant therapy (e.g., targeted therapy, immunotherapy) considered as appropriate; 3.Availability of complete preoperative clinical evaluation data, including imaging examinations (contrast-enhanced CT, MRI, renal dynamic scintigraphy, etc.) and laboratory indicators (e.g., renal function, tumor biomarkers); 4.Age >=18 years, no gender restriction; 5.No concurrent active malignancy and no severe comorbidities that would compromise the safety of surgery or adjuvant treatment; 6.Multidisciplinary team (MDT) evaluation confirming eligibility for surgery and individualized adjuvant therapy.

Exclusion criteria

Exclusion criteria: 1.Non-RCC cases or unclear pathological diagnosis; 2.Prior systemic targeted therapy, immunotherapy, or radiotherapy, with current recurrence or advanced metastatic disease; 3.Severe cardiopulmonary insufficiency, hepatic/renal failure, active infection, or other conditions precluding tolerance to surgery or adjuvant therapy; 4.Severe psychiatric disorders, cognitive impairment, or other conditions affecting study compliance; 5.Inability to comply with postoperative follow-up or anticipated inability to complete required assessments and data collection during the study period; 6.Participation in other interventional clinical trials that may interfere with study outcomes.

Design outcomes

Primary

MeasureTime frame
Postoperative renal function;Progression-Free Survival;Overall survival;

Secondary

MeasureTime frame
Postoperative complication incidence;Hospitalization duration;Postoperative recovery quality;

Countries

China

Contacts

Public ContactQi Zhang

Zhejiang Provincial People's Hospital

clinic@126.com+86 138 5801 9285

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026